Inclusion complex of β-cyclodextrin with diazepam and a physical mixture of these components were studied by solid-state (1)H NMR. The activation barrier for reorientation of the methyl group in the diazepam molecule was found not changed by complex formation with β-cyclodextrin. The complex formation resulted in a decrease in the number of water molecules and affected the relaxation time of β-cyclodextrin. By the atom-atom potential method the most probable configuration of the diazepam molecule inside β-cyclodextrin cavity was proposed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carres.2014.07.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of benzodiazepines in patients with status epilepticus requiring second-line antiseizure medication treatment.
Epilepsy Res
January 2025
Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Background: Status epilepticus (SE) is a life-threatening state that needs rapid and adequate treatment. Benzodiazepines (BZD) are used as a first-line treatment for SE, and if the desired effect is not achieved, second-line antiseizure medications are used.
Objective: To investigate whether the treatment with BZDs is performed adequately in patients with different subtypes of SE requiring second-line ASM treatment and, if not, to identify the factors influencing the suboptimal treatment.
Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS).
Seizure
January 2025
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL 36049, United States.
Purpose: On November 28, 2023, the U.S. FDA issued a Drug Safety Communication, warning that antiseizure medications (ASMs) levetiracetam and clobazam can cause a rare but serious reaction, drug reaction with eosinophilia and systemic symptoms (DRESS).
View Article and Find Full Text PDFInvestigation and Treatment of Infertility in a Female Black Rhinoceros (Diceros bicornis).
Zoo Biol
January 2025
Taronga Conservation Society Australia, Taronga Institute of Science and Learning, Mosman New South Wales 2088, Taronga Western Plains Zoo, Dubbo, New South Wales, Australia.
A zoo-based, 11-year-old, uniparous southern black rhinoceros (Diceros bicornis minor) failed to conceive after weaning a calf. Behavioral observation and fecal progestagen monitoring confirmed irregular estrous cycles. Serial transrectal reproductive ultrasound examination revealed the cause to be recurrent anovulatory hemorrhagic follicles (AHFs).
View Article and Find Full Text PDFA Rare Case of Posterior Fossa Syndrome Associated with Neuropathic Pain Successfully Treated with a Combination of Gabapentin, Diazepam and Baclofen-A Case Report and Literature Review.
Children (Basel)
November 2024
Department of Interdisciplinary Medicine, University of Bari and Aldo Moro, 70124 Bari, Italy.
Background: Posterior fossa syndrome (PFS), also known as cerebellar mutism syndrome, occurs in about 25% of pediatric patients undergoing resection of a posterior cranial fossa medulloblastoma. It is characterized primarily by mutism or reduced/impaired speech and may include variable symptoms such as motor dysfunction (apraxia, ataxia, hypotonia), supranuclear cranial nerve palsies, neurocognitive changes, and emotional lability. Long-term multidisciplinary rehabilitation is typically required, with recovery taking approximately six months, though many children experience long-term residual deficits.
View Article and Find Full Text PDFEvaluating the Efficacy of Levetiracetam on Non-Cognitive Symptoms and Pathology in a Tau Mouse Model.
Biomedicines
December 2024
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Alzheimer's disease (AD) is marked by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles (NFTs), leading to cognitive decline and debilitating non-cognitive symptoms. This study aimed to evaluate compounds from four different classes in a short-term (7-day) study using transgenic tau mice to assess their ability to reduce non-cognitive symptoms. The best candidate was then evaluated for longer exposure to assess non-cognitive symptoms, cognition, and pathology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!